Gemtesa Alternatives Compared
| Gemtesa (vibegron) | Botox (onabotulinumtoxinA) | Solifenacin |
|
|---|
| Gemtesa (vibegron) | Botox (onabotulinumtoxinA) | Solifenacin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Overactive Bladder. Gemtesa may also be used for purposes not listed in this medication guide. |
Prescription only
Botox is approved to treat many conditions, such as chronic migraine, involuntary muscle contractions or twitching, excessive sweating, increased saliva, and overactive bladder to name a few. Botox... View more |
Prescription only
Prescribed for Overactive Bladder, Urinary Incontinence, Urinary Frequency, Neurogenic Bladder, Neurogenic Detrusor Overactivity. Solifenacin may also be used for purposes not listed in this medication guide. View more |
Related suggestions Overactive Bladder
|
|||||||||||||||||||||||
| More about Gemtesa (vibegron) | More about Botox (onabotulinumtoxinA) | More about Solifenacin | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Gemtesa has an average rating of 7.7 out of 10 from a total of 201 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 12% reported a negative effect. |
Botox has an average rating of 5.7 out of 10 from a total of 473 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 41% reported a negative effect. |
Solifenacin has an average rating of 5.5 out of 10 from a total of 205 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 36% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Gemtesa side effects |
View all Botox side effects |
View all Solifenacin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Gemtesa prices |
View all Botox prices |
View all Solifenacin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other onabotulinumtoxinA brands include: Botox Cosmetic | VESIcare, VESIcare LS | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
94 hours |
N/A |
68 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 16 drugs are known to interact with Gemtesa:
|
A total of 120 drugs are known to interact with Botox:
|
A total of 496 drugs are known to interact with Solifenacin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
December 23, 2020 |
December 09, 1991 |
November 19, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.